Phase II clinical trial with gemcitabine and paclitaxel sequential monotherapy as first-line treatment for advanced non-small-cell lung cancer (SLCG 01-04)

[1]  Donna P. Ankerst,et al.  Handbook of statistics in clinical oncology , 2012 .

[2]  O. Belvedere,et al.  Sequential, alternating, and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature. , 2007, The oncologist.

[3]  R. Rosell,et al.  Quantification in the serum of the catalytic fraction of reverse telomerase: a useful prognostic factor in advanced non-small cell lung cancer. , 2006, Anticancer research.

[4]  S. Quercia,et al.  Trastuzumab plus estrogen suppression as salvage treatment in a case of liver failure due to metastatic breast cancer. , 2006, Anticancer research.

[5]  J. Crowley,et al.  Sequential Vinorelbine and Docetaxel in Advanced Non-small Cell Lung Cancer Patients Age 70 and Older and/or with a Performance Status of 2: A Phase II Trial of the Southwest Oncology Group (S0027) , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  Rafael Sirera,et al.  Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. , 2006, Lung cancer.

[7]  L. Chew,et al.  Phase II trial of gemcitabine and cisplatin sequentially administered in Asian patients with unresectable or metastatic non-small cell lung cancer. , 2006, Annals of the Academy of Medicine, Singapore.

[8]  R. Rosell,et al.  Is there a prognostic role of K-ras point mutations in the serum of patients with advanced non-small cell lung cancer? , 2005, Lung cancer.

[9]  R. Whittom,et al.  Sequential therapy with vinorelbine followed by gemcitabine in patients with metastatic non-small cell lung cancer (NSCLC), performance status (PS) 2 or elderly with comorbidities: A multicenter phase II trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  C. Kortsik,et al.  A phase II/III randomized study in advanced non-small cell lung cancer (NSCLC) with first line combination versus sequential gemcitabine (G) and docetaxel (D): Update on quality of life (QoL), toxicity, and costs , 2005 .

[11]  K. Kelly,et al.  Randomized Phase II Trial of Sequential Chemotherapy in Advanced Non-Small Cell Lung Cancer (SWOG 9806) , 2004, Clinical Cancer Research.

[12]  J. Pignon,et al.  Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. , 2004, JAMA.

[13]  Thomas J. Smith,et al.  American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  G. Vohwinkel,et al.  Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  David Harrington,et al.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.

[16]  E. Espinosa,et al.  Sequential therapy in advanced non-small-cell lung cancer with weekly paclitaxel followed by cisplatin-gemcitabine-vinorelbine. A phase II study. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  M. Ducreux,et al.  A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. , 2000, European journal of cancer.

[18]  M. Jiroutek,et al.  Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  T. Delozier,et al.  First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial) , 1999, British Journal of Cancer.

[20]  H. Wandt,et al.  Sequential cycles of high-dose chemotherapy with dose escalation of carboplatin with or without paclitaxel supported by G-CSF mobilized peripheral blood progenitor cells: a phase I/II study in advanced ovarian cancer , 1999, Bone Marrow Transplantation.

[21]  C. Belani,et al.  Chemotherapy for advanced non-small cell lung cancer: past, present, and future. , 1997, Seminars in oncology.

[22]  F. Shepherd,et al.  Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study. , 1996, European journal of cancer.

[23]  O. Brodin,et al.  Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials , 1995 .

[24]  J. Wanders,et al.  Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG) , 1994, British Journal of Cancer.

[25]  P Chomy,et al.  Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  G. Bonadonna.  Evolving concepts in the systemic adjuvant treatment of breast cancer. , 1992, Cancer research.

[27]  J L Pater,et al.  Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  R. Day,et al.  Treatment sequencing, asymmetry, and uncertainty: protocol strategies for combination chemotherapy. , 1986, Cancer research.

[29]  D. Khayat,et al.  Sequential administration of docetaxel followed by cisplatin-vindesine: a pilot study in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). , 2005, Bulletin du cancer.

[30]  F. Penault-Llorca,et al.  Impact of EGFR expression on colorectal cancer patient prognosis and survival. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  D. Garfield,et al.  Sequential versus concurrent paclitaxel and carboplatin for the treatment of advanced non-small cell lung cancer in elderly patients and patients with poor performance status: results of two Phase II, multicenter trials. , 2005, Lung cancer.

[32]  V Torri,et al.  Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  R. Gralla,et al.  Quality-of-life assessment in advanced lung cancer: considerations for evaluation in patients receiving chemotherapy. , 2004, Lung cancer.

[34]  L. Norton,et al.  Potential innovations in scheduling of cancer chemotherapy. , 1991, Important advances in oncology.